PPARA and metabolic dysfunction-associated steatotic liver disease: The n-3 PUFAs could downregulate sterol regulatory element-binding protein-1c (SREBP-1c) and upregulate peroxisome proliferator-activated receptor-alpha (PPAR-α) function, and therefore decreased de novo lipogenesis and increased free fatty acids oxidation, improved the biochemical and ultrasonographic manifestations of patients with NAFLD (40).